Molecular Understanding of HIV-1 Latency

Table 1

Licensed antiretroviral drugs.

Name	Trade name	Company	Launched
Nucleoside/nucleotide reverse transcriptase inhibitors
Zidovudine	Retrovir	GlaxoSmithkline	1987
Didanosine	Videx	Bristol-Myers Squibb	1991
Zalcitabine	HIVID	Roche	1992
Stavudine	Zerit	Bristol-Myers Squibb	1995
Lamivudine	Epivir	GlaxoSmithkline/shire pharmaceuticals	1998
Abacavir	Ziagen	GlaxoSmithkline	1999
Tenofovir	Viread	Gilead	2001
Emtricitabine	Emtriva	Gilead	2003
Non-nucleoside reverse transcriptase inhibitors
Nevirapine	Viramune	Boehringer Ingelheim	1996
Efavirenz	Sustiva, Stocrin	Bristol-Myers Squibb, Merck	1998
Delavirdine	Rescriptor	Pharmacia, Upjohn, Agouron, Pfizer	1999
Rilpivirine	Edurant	Tibotec Therapeutics	2011
Etravirine	Intelence	Tibotec Therapeutics	2008
Protease inhibitors
Saquinavir	Invirase	Hoffmann-La Roche	1995
Indinavir	Crixivan	Merck	1996
Ritonavir	Norvir	Abbott, GlaxoSmithkline	1996
Nelfinavir	Viracept	Agouron, Pfizer	1997
Amprenavir	Agenerase, Prozei	Vertex	1999
Lopinavir + Ritonavir	Kaletra, Aluvia	Abbott	2000
Atazanavir	Reyataz, Zrivada	Bristol-Myers Squibb, Novartis	2003
Fosamprenavir	Lexiva, Telzir	Vertex, GlaxoSmithkline	2003
Tipranavir	Aptivus	Boehringer Ingelheim	2005
Darunavir	Prezista	Tibotec	2006
Entry inhibitors
Enfuvirtide	Fuzeon	Trimeris, Roche	2003
Maraviroc	Celsentri, Selzentry	Pfizer	2007
Integrase strand transfer inhibitors
Raltegravir	Isentress	Merck & Co., Inc.	2007
Multi-class combination inhibitors
Efavirenz, Emtricitabine, and Tenofovir disoproxil fumarate	Atripla	Bristol-Myers Squibb and Gilead Sciences	2006
Emtricitabine, Rilpivirine, and Tenofovir disoproxil fumarate	Complera	Gilead Sciences	2011